Coadministration of GA2 Sporozoites With Adjuvants
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study will assess the coadministration of genetically attenuated Plasmodium falciparum
∆mei2 (GA2) sporozoites with adjuvants (BCG and YF-17D vaccination and imiquimod cream).
Primary outcomes will be safety, tolerability and protective efficacy against CHMI.